JBF Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

JBF Capital’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$20K	–	173
2018 Q3	$20K	Buy	+1,000	New	+$22.8K	﹤0.01%	131

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JBF Capital's AMAG Position: Q4 2018 in Review

JBF Capital sold out of AMAG Pharmaceuticals (AMAG) in Q4 2018, closing a stake of 1,000 shares — an estimated $20K sold.

JBF Capital first reported a position in AMAG in Q3 2018 and held it in 1 quarter. The position peaked at $20K in Q3 2018. 190 funds tracked by Wall St. Rank hold AMAG as of Q4 2018.

JBF Capital reported no remaining AMAG Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
JBF Capital sold 1,000 AMAG Pharmaceuticals shares in Q4 2018, an estimated $20K.
JBF Capital first reported a position in AMAG Pharmaceuticals in Q3 2018 and held it in 1 quarter.
JBF Capital's AMAG Pharmaceuticals position peaked at $20K in Q3 2018.
190 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.